Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS

SIMPLE SUMMARY: Treatment results of acute myeloid leukemia (AML) in elderly patients are unsatisfactory. We investigated in an open label randomized phase II study whether addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy would improve outcome in this population. 231 AM...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancers (Basel)
Main Authors: Janssen, Jeroen, Löwenberg, Bob, Manz, Markus, Bargetzi, Mario, Biemond, Bart, Borne, Peter von dem, Breems, Dimitri, Brouwer, Rolf, Chalandon, Yves, Deeren, Dries, Efthymiou, Anna, Gjertsen, Bjørn-Tore, Graux, Carlos, Gregor, Michael, Heim, Dominik, Hess, Urs, Hoogendoorn, Mels, Jaspers, Aurelie, Jie, Asiong, Jongen-Lavrencic, Mojca, Klein, Saskia, van der Klift, Marjolein, Kuball, Jürgen, van Lammeren-Venema, Danielle, Legdeur, Marie-Cecile, van de Loosdrecht, Arjan, Maertens, Johan, Kooy, Marinus van Marwijk, Moors, Ine, Nijziel, Marten, van Obbergh, Florence, Oosterveld, Margriet, Pabst, Thomas, van der Poel, Marjolein, Sinnige, Harm, Spertini, Olivier, Terpstra, Wim, Tick, Lidwine, van der Velden, Walter, Vekemans, Marie-Christiane, Vellenga, Edo, de Weerdt, Okke, Westerweel, Peter, Stüssi, Georg, van Norden, Yvette, Ossenkoppele, Gert
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2021
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7914531/
https://ncbi.nlm.nih.gov/pubmed/33562393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13040672
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki